Summit Therapeutics Inc. — Director's Dealing 2023

Oct 16, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2023-10-13

Reporting Person: Soni Manmeet Singh (Director, Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-13	Common Stock	P	2976190	$1.68	Acquired	2976190	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-10-13	Stock Option (right to buy)	$1.68	A	14000000	Acquired	2033-10-13	Common Stock (14000000)	Direct

Footnotes

F1: The Issuer entered into a securities purchase agreement with the Reporting Person, pursuant to which the Issuer agreed to issue and sell to the Reporting Person shares of the Issuer's Common Stock at a per share purchase price equal to $1.68.

F2: The option was granted on October 13, 2023. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on October 13, 2024. Note this does not include an additional 14,000,000 options which were granted on October 13, 2023 and are subject to the satisfaction of performance conditions based on market capitalization and revenue targets.

F3: Not applicable.